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Non-Hodgkin Lymphoma
Introduction
Mature B-cell non-Hodgkin lymphoma (NHL) is the most
common hematologic malignant neoplasm in adults in most
populations worldwide.1 The incidence of indolent NHL has
increased since 1989 in the Netherlands, but that of aggres-
sive neoplasms has remained stable.2 The incidence of NHL in
Europe and the USA has been stable for over 10 years.3,4
Survival has increased for patients with mature B-cell neo-
plasms, resulting in decreasing mortality from these condi-
tions since the beginning of this century. The diverging trends
in incidence and mortality have resulted in an increased
prevalence of NHL in the Netherlands.2,3
There is a clear difference in biological behavior between
subtypes of B-cell NHL, which affects survival estimates
resulting in an initially better survival for patients with indo-
lent subtypes of B-cell NHL. The ongoing mortality of
patients with indolent NHL with prolonged follow-up is most
likely caused by further disease progression.5,6
Survival estimates for cancer patients, traditionally reported
from the time of cancer diagnosis, are not generally applicable
to patients who have already survived for some time after ini-
tial diagnosis and treatment. Especially for aggressive NHL
these standard survival curves at diagnosis are rather pes-
simistic since they are based on all patients, including those
who died within the first few years.2 Conditional relative sur-
vival analysis is a method for estimating the survival rate for
those who have already survived for a certain period of time.7-
9 Such survival estimates seem useful for cancer survivors,
yielding more relevant information about their current prog-
nosis, which can be used for personal health-related planning
and by treating physicians for planning optimal cancer sur-
veillance.8,9 Furthermore, they give information about excess
mortality which might be caused by either the underlying
NHL, late treatment-related toxicity, and/or co-morbidity.
Most previous studies on conditional survival for patients
with NHL did not subdivide between the distinct entities of
NHL,10-12 except one study on diffuse large B-cell lymphoma
that displayed conditional survival up to 5 years after diagno-
sis.13 It is, however, obvious that better information would be
provided by subdividing these entities, each with a different
prognosis. 
With the marked increase in the number of NHL patients
and their improving survival, there is a growing need for a
more up-to-date and subgroup-specific analysis of actual sur-
vival. In this study we estimated conditional 5-year relative
survival rates for B-cell NHL patients, according to morpho-
logical entity, grade, gender, age, and stage at each additional
year survived up to 16 years after diagnosis.
Methods
Data collection
The population-based data used were from the nationwide
Netherlands Cancer Registry.14 Information on patients’ characteristics
as well as tumor characteristics such as morphology,15 and Ann Arbor
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Survival rates determined at diagnosis are often too negative for cancer survivors. Conditional relative survival
reflects actual prognosis during follow-up better. Data from all 54,015 patients newly diagnosed in the Netherlands
with B-cell non-Hodgkin lymphoma during 1989-2008, aged 15-89 years (Netherlands Cancer Registry), were used.
Five-year conditional relative survival was computed for every additional year of survival up to 16 years after diag-
nosis, according to entity, grade, gender, age, and Ann Arbor stage. The prognosis for survivors of indolent B-cell
non-Hodgkin lymphoma improved slightly with each additional year survived up to 91%. For patients with aggres-
sive non-Hodgkin lymphoma conditional relative survival improved strongly during the first year after diagnosis
(from 48% to 68%) and gradually thereafter to 93% after 16 years. There were differences between morphological
entities. Initial differences in conditional relative survival at diagnosis between groups with different disease stages
became smaller with increasing number of years survived. Age remained a prognostic indicator, also after prolonged
follow-up. These results help caregivers to plan optimal surveillance and inform patients about their actual progno-
sis during follow-up. Long-lasting excess mortality among patients with B-cell non-Hodgkin lymphoma indicates
the need for additional care long after their diagnosis.
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stage,16 were obtained routinely from the medical records about 9
months after diagnosis. 
In addition to passive follow-up via the hospitals, date of death
was also retrieved from the Municipal Personal Records Database.
Follow-up of vital status was complete until January, 1st, 2010. 
For the present study, all patients with mature B-cell NHL newly
diagnosed in the period 1989-2008 in the Netherlands were includ-
ed (n=54,015). Patients with plasma cell neoplasms were excluded.
NHL entities were defined according to the World Health
Organization classification, 4th edition.18 The exact codes used for
each entity are described in a previous publication.2 Sufficient
patients were available to report the entity-specific conditional rel-
ative survival for chronic lymphocytic leukemia/small lymphocyt-
ic lymphoma (CLL), marginal zone lymphoma (MZL), lympho-
plasmacytic lymphoma (LPL), follicular lymphoma (FL), mantle cell
lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL).
We also used two major diagnostic subgroups, based on a com-
bination of entities of more or less similar clinical behavior and
comparable response to therapies: indolent and aggressive B-cell
neoplasms. The entities included in each subgroup are shown in
Table 1. Unspecified cases were excluded from these analyses.
Patients younger than 15 years and older than 89 years were
excluded from the analysis, as were cases diagnosed at autopsy.
Patients were divided into four age groups (15-44, 45-59, 60-74,
and 75-89 years old). Patients aged 15-29 and 30-44 years were
merged, because of the small numbers.
Statistical analyses
Relative survival is an approximation of disease-specific sur-
vival. It is calculated as the absolute survival among cancer
patients divided by the expected survival of a comparable group
from the general population (same period, age, and gender).
Expected survival was calculated from population life tables from
the Netherlands, according to the Ederer II method.19
Period analysis20,21 was used to provide up-to-date survival esti-
mates; all observations included in the analysis are left-truncated
at the beginning of the period of interest, in addition to being
right-censored at its end. Furthermore, to enable the estimation of
even more up-to-date survival, hybrid analysis was used.22
Five-year relative survival rates were computed for every addi-
tional year of survival up to 15 years after diagnosis, conditional
on being alive at the beginning of that year (conditional 5-year rel-
ative survival, CRS), unadjusted for other variables. Conditional
survival was computed according to disease entity, grade, gender,
15-year age group, and stage of disease. For the analysis according
to period of diagnosis (1995-2000 versus 2003-2008) conditional 3-
year relative survival rates were computed, since follow-up time
for patients diagnosed in 2003-2008 was limited. When the CRS
persistently reached 95% for a group of patients, they were con-
sidered to have minimal excess mortality compared to the general
population. For the calculation of CRS estimates, a saturated
Poisson regression model for period analysis23 was used.
Results
Table 1 presents the number of patients per entity of B-
cell NHL. For entities for which there were sufficient num-
bers of patients, the numbers of patients available for sur-
vival analysis at diagnosis and after 5 and 10 years are
shown, according to gender and age group when possible,
in Table 2. This table also presents the last year for which
a reliable estimate of the CRS could be given, as well as
the CRS at diagnosis and 5 and 10 years after diagnosis. 
The prognosis (CRS) for patients with indolent B-cell
NHL improved slightly with each additional year survived
after diagnosis, especially for those with FL (from 72% at
diagnosis to 86% after 10 years) and MZL (from 80% at
diagnosis to 93% after 10 years) (Figure 1). However, the
CRS of patients with CLL or LPL was stable over time
S.A.M. van de Schans et al.
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Table 1. Number of patients per entity of B-cell non-Hodgkin lymphoma in the Netherlands 1989-2008
Group WHO classification Number of patients Entitya
Indolent
Chronic lymphocytic leukemia/small lymphocytic lymphoma 13,549 CLL
B-cell prolymphocytic leukemia 153 -
Splenic marginal zone lymphoma 203
Extranodal marginal zone lymphoma 2,196 MZL
Nodal marginal zone lymphoma 432
Hairy cell leukemia 990 -
Lymphoplasmacytic lymphoma 3,425 LPL
Follicular lymphoma, grade I-II 6,802 FL
Primairy cutaneous follicle center lymphoma 310
Aggressive
Follicular lymphoma, grade III 912
Mantle cell lymphoma 2,440 MCL
Diffuse large B-cell lymphoma (DLBCL) 17,010
Primary DLBCL of the central nervous system 1,011 DLBCLPrimary cutaneous DLBCL, leg type 438
Primary mediastinal large B-cell lymphoma 106
Primary effusion lymphoma 11 -
Burtkitt lymphoma 616 -
Other, unclassifiable B-cell neoplasms 3,408 -
aCLL: chronic lymphocytic leukemia/small lymphocytic lymphoma, MZL: marginal zone lymphoma (splenic, extranodal and nodal), LPL: lymphoplasmacytic lymphoma, FL: follicular
lymphoma (grade I, II & III, including primary cutaneous follicle center lymphoma), MCL: mantle cell lymphoma, DLBCL: diffuse large B-cell lymphoma (including central nervous
system, cutaneous, mediastinal).
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since diagnosis (around 70%). The prognosis of CLL start-
ed to improve after 9 years (from 71% to 81% after 14
years). CRS improved greatly for DLBCL survivors during
the first year after diagnosis (from 48% at diagnosis to
71% after 1 year). In the additional years after diagnosis
the improvement in the prognosis of DLBCL patients lev-
eled off, but became slightly higher (87% after 10 years)
than that of patients with the indolent B-cell NHL subtype
CLL (74% after 10 years) (Figure 1). MCL survivors had
the worst prognosis of patients with all entities, although
this prognosis gradually inproved with each additional
year survived after diagnosis (from 40% at diagnosis to
68% after 6 years). The patterns of CRS for indolent and
aggressive B-cell NHL were similar for males and females
(data not shown). However, a significantly better CRS was
found for female patients with CLL compared to male
patients with CLL (Table 2). 
Five-year relative survival at diagnosis was better for
younger patients than for elderly patients for both indo-
lent and aggressive NHL [at diagnosis: 88% for those 15-
Actual prognosis of NHL survivors
haematologica | 2014; 99(2) 341
Table 2. Conditional survival for patients with B-cell non-Hodgkin lymphoma in the Netherlands 1989-2008 (n=54,015).
N. of patients available Reliable Conditional 5-year
for estimation of conditional estimate relative survival (%)
relative survival up to yeara
after 5 years 10
Diagnosis (0) At diagnosis At 5 years At 10 years 
(95% CI) (95% CI) (95% CI)
CLL
Overall 6362 2366 641 14 71 (70-72) 71 (69-72) 74 (71-78)
Males 3620 1246 336 12 68 (66-70)$ 67 (65-70) $ 73 (68-77)
Females 2742 1120 305 13 75 (73-77) 75 (72-78) 76 (71-81)
15-44 years 259 139 - 9 89 (85-93) $ 82 (76-87) $ -
45-59 years 1539 721 234 12 82 (80-84) 76 (73-79)* 77 (72-81)
60-74 years 3143 1212 320 12 73 (71-74) 69 (66-71) 71 (66-76)
75-89 years 1422  295 - 5 59 (56-61) 64 (58-71) -
MZL
Overall 1370 559 165 13 80 (78-83) 90 (87-93)* 93 (87-99)*
Males 663 275 77 11 79 (76-82) 89 (84-94)* 96 (88-103)*
Females 708 284 89 10 82 (79-84) 91 (87-95)* 91 (83-99)
15-44 years 180 99 51 15 95 (92-98)$ 98 (96-101) $ 95 (90-101)
45-59 years 401 186 54 10 89 (86-92) 90 (86-94) 93 (86-101)
60-74 years 575 233 - 8 79 (75-82) 89 (84-95)* -
LPL
Overall 1609 619 172 10 71 (69-74) 68 (64-71) 70 (64-77)
Males 919 322 - 7 71 (68-74) 65 (60-70) -
Females 690 297 - 6 72 (68-75) 71 (66-76) -
45-59 years 374 186 - 7 82 (78-86)$ 80 (74-85)$ -
60-74 years 726 291 - 6 73 (69-76) 61 (56-66)* -
FL
Overall 3961 1696 614 15 72 (71-73) 79 (77-81)* 86 (83-89)*
Males 1965 813 287 15 72 (70-74) 78 (75-80)* 87 (82-91)*
Females 1996 883 327 14 72 (70-74) 80 (77-82)* 84 (81-89)*
15-44 years 755 448 199 15 85 (82-87)$ 90 (88-93)*$ 88 (84-92)
45-59 years 1577 719 268 15 78 (76-80) 80 (77-82) 88 (84-91)*
60-74 years 1274 453 - 9 67 (65-69) 72 (68-76) -
MCL
Overall 650 215 80 6 40 (37-42) 61 (55-66)* -
DLBCL
Overall 5621 2706 1066 15 48 (47-49) 85 (84-87)* 87 (84-89)*
Males 2956 1409 571 15 49 (48-50) 86 (83-88)* 90 (86-93)*
Females 2665 1297 496 16 48 (46-49) 84 (83-87)* 84 (80-88)*
15-44 years 1126 716 368 15 69 (67-71)$ 95 (93-96)*$ 97 (95-99)*$
45-59 years 1620 884 386 15 61 (59-62) 87 (85-89)* 88 (84-91)*
60-74 years 2010 885 282 12 47 (45-49) 80 (77-83)* 77 (72-83)*
75-89 years 865 - - 4 31 (29-33) - -
aStandard error ≤ 5% of survival rate; BCLL = chronic lymphocytic leukemia/small lymphocytic lymphoma, MZL = marginal zone lymphoma (splenic, extranodal and nodal), LPL =
lymphoplasmacytic lymphoma, FL = follicular lymphoma (grade I, II & III, including primary cutaneous follicle center lymphoma), MCL = mantle cell lymphoma, DLBCL = diffuse
large B-cell lymphoma (including central nervous system, cutaneous, mediastinal); *A significant (P<0.05) improvement in CRS since diagnosis; $A significant (P<0.05) difference
between subgroups within an NHL entity.
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44 years versus 59% for those 75-89 years with indolent
NHL (P<0.05) and 69% for those 15-44 years versus 31%
for those 75-89 years with aggressive NHL (P<0.05)]. This
initial difference in relative survival between patients in
different age groups remained among patients with both
indolent and aggressive NHL [CRS after 5 years: 90% for
those 15-44 years versus 66% for those 75-89 years with
indolent NHL (P<0.05) and 94% for those 15-44 years ver-
sus 75% for those 75-89 years with aggressive NHL
(P<0.05)]. Similar results were found for all examined enti-
ties of NHL (Figure 2A-D). Age does, therefore, remain an
important prognostic factor.
As expected, patients with higher stages of FL had a
poorer CRS at diagnosis than patients with lower stages of
FL [86% (stage I-II) versus 66% (stage III-IV, P<0.05)]. This
initial difference in survival at diagnosis between stage
groups for patients with FL decreased somewhat with
time survived since diagnosis, but remained statistically
significant (CRS after 10 years: 92% versus 77%, P<0.05)
(Figure 3A). For patients with DLBCL a similar difference
in CRS at diagnosis was found (64% for stage I versus 88%
for stage II-IV, P<0.05), which largely disappeared after
patients had survived for 5-10 years (after 10 years: 88%
versus 86%) (Figure 3B).
For indolent and aggressive NHL 3-year relative survival
at diagnosis was significantly better in 2003-2008 than in
1995-2000 (3-year relative survival at diagnosis was 79%
S.A.M. van de Schans et al.
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Figure 2. (A) Conditional 5-year relative survival for every additional year survived after initial diagnosis of patients with chronic lymphocytic
leukemia, according to age group. (B) Conditional 5-year relative survival for every additional year survived after initial diagnosis of patients
with marginal zone lymphoma, according to age group. (C) Conditional 5-year relative survival for every additional year survived after initial
diagnosis of patients with follicular lymphoma, according to age group. (D) Conditional 5-year relative survival for every additional year sur-
vived after initial diagnosis of patients with diffuse large B-cell lymphoma, according to age group.
Figure 1. Conditional 5-year relative survival for every additional
year survived after initial diagnosis of patients with B-cell non-
Hodgkin lymphoma, according to entity.
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versus 85% for indolent NHL and 49% versus 60% for
aggressive NHL; both P<0.05). This difference in survival
decreased with years since diagnosis, especially for aggres-
sive NHL (Figure 4).
Minimal excess mortality (CRS >95%) only occurred in
younger patients (15-44 years) with MZL from diagnosis,
DLBCL from 6 years after diagnosis and FL for those who
had already survived for 15 years after diagnosis. For all
other groups of NHL patients survival remained lower
compared to that in the general population.
Discussion
The prognosis for survivors with any subtype of indo-
lent B-cell NHL improved slightly, up to 80-90%, with
each additional year of survival after diagnosis. For
patients with DLBCL CRS improved markedly during the
first year after diagnosis (from 48% at diagnosis to 71%)
and thereafter gradually to 95% after 16 years. Differences
in survival by gender were small. Age remained a prognos-
tic indicator, also after prolonged follow-up. Initial differ-
ences in CRS at diagnosis between groups with different
stages of disease became smaller with increasing number
of years survived. 
To the best of our knowledge, this is the first study
reporting separately on conditional 5-year relative survival
for several entities of NHL and for the subgroups of
patients with indolent or aggressive mature B-cell NHL
alive up to 16 years after diagnosis according to age, gen-
der, and Ann Arbor stage. We were able to compute up-to-
date and detailed CSR using high-quality data from the
long-standing Netherlands Cancer Registry, and by appli-
cation of period analysis.20 The results give insight into
excess mortality for each additional year after diagnosis a
group of NHL patients has survived. 
For indolent lymphoma conditional survival rates
improved slightly in the years following diagnosis but
remained lower than those in the general population. This
probably reflects the natural history of this chronic dis-
ease. Patients with indolent lymphomas have mostly been
managed by a primary wait-and-see strategy without the
achievement of a long-lasting complete remission.24-26 This
strategy is more common in CLL and LPL patients than in
MZL and FL patients. This is reflected by the larger
improvement in prognosis in patients with the latter enti-
ties. In the younger age group of patients with the indo-
lent B-cell NHL entities FL and MZL minimal excess mor-
tality was observed, suggesting cure of their disease at
diagnosis for MZL and 15 years after diagnosis for FL.
Unfortunately, we could not pin down any association
with treatment, because we could not document the exact
therapy or therapies of each patient and subgroups would
have become too small for analysis. 
For patients with DLBCL survival improved greatly dur-
ing the first years after diagnosis, resulting in a better prog-
nosis 1-4 years after diagnosis, which is in line with the
main treatment goal in this disease: achievement of a sus-
tained complete remission. The long-term prognosis of
individuals with DLBCL became similar to that of the gen-
eral population for younger patients who had survived for
6 years. This suggested that many patients can be consid-
ered cured. However, after prolonged follow-up relevant
cardiovascular and second tumor effects cannot be exclud-
ed. A remaining excess mortality among NHL patients
aged 45 years or older also appeared in some studies from
Europe, as well as Canada and Australia.10-12 Late recur-
rences of lymphoma are likely as well as late effects of
chemotherapy and radiotherapy (mainly cardiovascular
disease and secondary tumors).27,28 Furthermore, a large
proportion of NHL patients reported a high level of fatigue
up until 10 years after diagnosis.29 The gradual improve-
ment in prognosis for patients with MCL could indicate
that secondary therapies resulted in cure for some of these
individuals. 
Survival of patients with B-cell NHL depends on several
pretreatment prognostic variables.5,30-32 In this study the
prognostic effect of Ann Arbor stage at diagnosis
decreased with time since diagnosis. In other words, con-
ditional survival improved more with time since diagnosis
in the groups with more advanced stage disease. This
decrease in prognostic value of stage (and probably also
Actual prognosis of NHL survivors
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Figure 3. (A) Conditional 5-year relative survival for every additional year survived after initial diagnosis of patients with follicular lymphoma,
according to Ann Arbor stage. (B) Conditional 5-year relative survival for every additional year survived after initial diagnosis of patients with
diffuse large B-cell lymphoma (including central nervous system, cutaneous, mediastinal), according to Ann Arbor stage.
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other disease-related prognostic factors) during follow-up
is in line with the known natural behavior of the disease,
especially of aggressive NHL. Initially mortality is largely
due to disease progression. For those who survive this
period the disease is either in complete remission because
of successful therapy or the less aggressive clinical behav-
ior results in a decreased impact of disease-related prog-
nostic factors. This decrease of impact of stage on survival
during follow-up confirms the earlier published observa-
tion of Moller et al. in DLBCL patients.13
In contrast, age at diagnosis remained of prognostic
value in our study during prolonged follow-up. The nega-
tive effect of older age on long-term survival generally
reflects the reduced ability of older patients to tolerate
intensive salvage therapy, the age-related propensity for
late doxorubicin-induced cardiomyopathy, but also
increased mortality from co-morbidity.31,33-37
The prognosis of B-cell NHL patients has improved in
recent decades due to the introduction of more effective
drugs for newly diagnosed and relapsed patients (e.g. rit-
uximab),38,39 to which the large scale HOVON trials may
have contributed in the Netherlands. Furthermore,
research towards more accurate diagnostics, better prog-
nostication, and better supportive care could have
improved the prognosis of patients diagnosed in more
recent years. This appears to be reflected in our data.
Understandably, the direct effect of these therapies, diag-
nostics, and prognostication on conditional survival could
not be demonstrated in this population-based study.
Long-term follow-up is required to calculate clinically
informative measures of conditional survival. The
Netherlands Cancer Registry has collected population-
based data since 1989, thus long-term follow-up informa-
tion is available. However, a changing classification system,
improvements in disease detection and evolving cancer reg-
istration procedures may have contributed to temporal
trends in incidences of lymphoma entities.40 Variation in the
incidence of entities of lymphoma over time could have
resulted in differences in prognosis per period of diagnosis.
A web-based tool has been constructed to make condi-
tional relative survival estimates available for physicians
treating cancer patients. A user-friendly program provides
insight into CRS estimates for every additional year after
diagnosis survived for several tumor sites, including indo-
lent and aggressive NHL, according to gender and age at
diagnosis. This program (www.dutchcancersurvival.com) is
available for caregivers, for counseling their patients, e.g.
concerning the planning of their remaining life. However,
they should of course also consider the actual condition of
the patient.
In conclusion, with the marked increase in the number
of NHL survivors there is a growing need for information
of actual prognosis during follow-up, which is provided
by conditional survival figures. These figures can help
caregivers to plan optimal cancer surveillance and patients
to get on with the planning of their remaining life. Long-
lasting excess mortality for B-cell NHL patients indicates
the need for prolonged care following diagnosis, with a
consequent impact on patients and the healthcare system.
Acknowledgments
This research was performed within the framework of the proj-
ect ‘Insight into health aspects of long-term cancer survivors in the
Netherlands – a tool for caregivers and cancer survivors’ (Dutch
Cancer Society Grant IKZ 2009-4316). We acknowledge the
dedicated data collection by the registrars of the Netherlands
Cancer Registry and Dr John Raemaekers, Depts. of
Hematology, Radboud University Medical Center, Nijmegen and
of Rijnstate Hospital, Arnhem, the Netherlands for critically
reviewing a final version of the paper. 
Authorship and Disclosures
Information on authorship, contributions, and financial & other
disclosures was provided by the authors and is available with the
online version of this article at www.haematologica.org.
S.A.M. van de Schans et al.
344 haematologica | 2014; 99(2)
Figure 4. Conditional 3-year relative survival for every additional year
survived after initial diagnosis of patients with NHL according to
grade and period of diagnosis.
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